Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis

BACKGROUND: Natalizumab treatment provides a model for non-inflammation-induced disease progression in multiple sclerosis (MS). OBJECTIVE: To study serum contactin-1 (sCNTN1) as a novel biomarker for disease progression in natalizumab-treated relapsing-remitting MS (RRMS) patients. METHODS: Eighty-n...

Descripción completa

Detalles Bibliográficos
Autores principales: van Lierop, Zoë YGJ, Wieske, Luuk, Koel-Simmelink, Marleen JA, Chatterjee, Madhurima, Dekker, Iris, Leurs, Cyra E, Willemse, Eline AJ, Moraal, Bastiaan, Barkhof, Frederik, Eftimov, Filip, Uitdehaag, Bernhard MJ, Killestein, Joep, Teunissen, Charlotte E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689420/
https://www.ncbi.nlm.nih.gov/pubmed/33890520
http://dx.doi.org/10.1177/13524585211010097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689420/
https://www.ncbi.nlm.nih.gov/pubmed/33890520
http://dx.doi.org/10.1177/13524585211010097

Ejemplares similares